Dog Vaccines Global Market Report 2024

The global dog vaccines market has grown strongly in recent years. It will grow from $3.43 billion in 2023 to $3.64 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to factors such as the shift from paper-based to digital documentation, a focus on regulatory compliance and records management, corporate digitization initiatives, the introduction of document imaging and scanning technologies, and the emergence of enterprise content management (ECM) solutions.

The global dog vaccines market is expected to see strong growth in the next few years. It will grow to $4.76 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the forecast period can be attributed to the adoption in emerging markets and small to medium enterprises (SMEs), a heightened focus on user experience and mobile accessibility, migration to hybrid and cloud-centric models, an increase in data security concerns, and a growing demand for remote work solutions. Major trends in the forecast period encompass the integration with business applications, an emphasis on remote work and collaboration tools, the implementation of blockchain technology, the adoption of mobile-friendly interfaces, and a focus on cybersecurity and compliance in document management solutions.

The dog vaccines market is set for growth, fueled by the increasing adoption of pet dogs. Pet dogs, serving as domesticated companion animals, are becoming integral members of households. Dog vaccines, administered in a series from puppyhood into adulthood, stimulate the immune system, enabling dogs to resist microorganisms and exhibit either no illness or less severe symptoms. According to the National Pet Owners Survey by the American Pet Products Association for 2021-2022, 70% of U.S. households, equivalent to 90.5 million homes, owned pets. Notably, 69 million U.S. households embraced dogs as pets, representing the highest ownership compared to other animals. This surge in pet dog adoption is a key driver for the growth of the dog vaccines market.

The dog vaccines market is anticipated to witness growth due to the escalating prevalence of zoonotic diseases. Zoonotic diseases, capable of transmission between animals and humans, necessitate preventive measures. Dog vaccines play a crucial role in averting the transmission of zoonotic diseases from dogs to humans, contributing to broader public health initiatives. A report by the Council on Foreign Relations in February 2023 highlighted that up to 75% of newly discovered infectious diseases and 60% of recognized infectious diseases have zoonotic origins. These zoonoses cause significant global health concerns, resulting in millions of fatalities and disease episodes annually. The growing prevalence of zoonotic diseases is a driving factor for the dog vaccines market.

Technological advancements are emerging as a prominent trend in the dog vaccines market. Leading companies in the market are leveraging novel technologies for vaccine development. Merck Animal Health, a notable player, introduced Nobivac Intra-Trac Oral BbPi in September 2022. This oral vaccine, featuring mucosal protection and easy administration, represents a technological leap forward. It employs the innovative Immuno-Mist-R technology by Intervet, a Merck & Co subsidiary, significantly enhancing mucosal surface area contact. This technological progress in vaccine development contributes to the effectiveness and ease of administration in the dog vaccines market.

Major companies in the dog vaccines market are concentrating on innovative rabies vaccines to gain a competitive edge. The introduction of a three-dose rabies vaccine by Cadila Pharmaceuticals exemplifies this focus on innovation. Launched in April 2022, ThRabis is a recombinant nanoparticle-based rabies G protein vaccine, utilizing virus-like particle technology. The vaccine, generated from cloned genes expressed in insect cells, neutralizes the rabies virus and prevents its attachment to cells. This innovation in rabies vaccines addresses key aspects of effectiveness, accessibility, and administration, positioning companies at the forefront of the competitive landscape in the dog vaccines market.

In January 2021, Boehringer Ingelheim, a prominent Germany-based pharmaceutical company with an extensive portfolio of pharmaceutical products, including animal vaccines, entered into a partnership with PetMedix. The collaboration aims to develop new and transformative antibody therapeutics for companion animals, leveraging PetMedix's proprietary Ky9 platform. In this joint effort, PetMedix is responsible for the discovery of therapies against key targets, while Boehringer Ingelheim undertakes the development and commercialization of these therapies. PetMedix, a UK-based developmental-stage veterinary biopharmaceutical company, brings innovation to veterinary medicine through its Ky9TM platform, capable of rapidly and efficiently generating fully canine therapeutic antibodies. The collaboration signifies Boehringer Ingelheim's commitment to advancing veterinary medicine and expanding its offerings in the field of companion animal healthcare.

Major companies operating in the dog vaccines market report are Bayer AG, Vetoquinol S.A., Boehringer Ingelheim GmbH, Ceva Sante Animale, Heska Corporation, Merck & Co. Inc., Virbac Animal Health Pvt. Ltd., Elanco Animal Health Incorporated, Zoetis Inc., CZ Vaccines, Indian Immunologicals Ltd., Sanofi S.A., CyMedica Orthopedics Inc., Creative Biolabs Inc., Meiji Holdings Co. Ltd., Bioveta A.S., Phibro Animal Health Corporation, Hester Biosciences Limited, High Speed Digieal Processor Architecture Pvt. Ltd., Dechra Pharmaceuticals PLC, Idexx Laboratories Inc., Norbrook Inc., Biogenesis Bago SA, Vaxxinova India Private Limited, Bimeda Animal Health Ltd., Lohmann Animal Health GmbH, Biovac Ltd., Zenex Animal Health India Pvt. Ltd., Instituto Rosenbusch S A, and Pfizer Inc.

Asia-Pacific was the largest region in the dog vaccines market in 2023. The regions covered in the dog vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dog vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key categories of dog vaccines encompass attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, and recombinant vaccines. Attenuated live vaccines involve creating a vaccine by reducing the virulence of a pathogen while maintaining its viability. Administration methods include subcutaneous, intramuscular, and intranasal routes, catering to dogs below 6 months and those above 6 months.

This report provides dog vaccines market statistics, including dog vaccines industry global market size, regional shares, competitors with an dog vaccines market share, detailed dog vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the dog vaccines industry. This dog vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dog vaccines market consists of sales of vaccines for dogs including core dog vaccines, and non-core dog vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.